Finding a molecule that affects a single enzyme is a delicate task because that enzyme may also be important for normal brain functions. The USC team screened compounds that dial down cPLA2 activity without erasing its useful roles. If these compounds prove safe and effective in follow-up studies, they could offer a way to reduce damaging inflammation while preserving healthy brain signaling. That balance matters for designing treatments that help patients maintain quality of life.
This line of research connects directly to human potential: preserving cognitive function influences independence, creativity, and how people engage with their communities as they age. The paper raises questions about who might benefit most from such therapies and how early intervention could change outcomes. Read the full article to explore the evidence, the challenges ahead, and what this might mean for inclusive strategies to protect brain health.
USC researchers have identified potential new drug compounds that may reduce the brain inflammation linked to Alzheimer’s disease, especially in people with the high-risk APOE4 gene. The compounds target cPLA2, an enzyme that seems to fuel harmful inflammation while also being important for normal brain activity.
